Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brid Devlin

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Pharmaceutical Research|August 1, 2014
Formulation and characterization of polymeric films containing combinations of antiretrovirals (ARVs) for HIV preventionAyman Akil, Hrushikesh Agashe, Charlene S Dezzutti, et al.
International Journal of Pharmaceutics|April 19, 2019
Development and pharmacokinetics of a combination vaginal ring for sustained release of dapivirine and the protein microbicide 5P12-RANTESJohn W McBride, R Karl Malcolm, Nicola Dias, et al.
Frontiers in Reproductive Health|July 24, 2023
Participant experiences with a multipurpose vaginal ring for HIV and pregnancy prevention during a phase 1 clinical trial: learning from users to improve acceptabilityMary Kate Shapley-Quinn, Mei Song, Beatrice A Chen, et al.
International Journal of Pharmaceutics|July 31, 2016
Matrix and reservoir-type multipurpose vaginal rings for controlled release of dapivirine and levonorgestrelPeter Boyd, Susan M Fetherston, Clare F McCoy, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 14, 2015
A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal FilmKatherine E Bunge, Charlene S Dezzutti, Lisa C Rohan, et al.
International Journal of Pharmaceutics: X|January 3, 2022
Silicone elastomer formulations for improved performance of a multipurpose vaginal ring releasing dapivirine and levonorgestrelYahya H Dallal Bashi, Diarmaid J Murphy, Clare F McCoy, et al.
Plos One|June 5, 2024
Phase 1 randomized trials to assess safety, pharmacokinetics, and vaginal bleeding associated with use of extended duration dapivirine and levonorgestrel vaginal ringsSharon L Achilles, Clifton W Kelly, Craig J Hoesley, et al.
The Lancet. HIV|February 4, 2021
Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension studyAnnalene Nel, Neliëtte van Niekerk, Ben Van Baelen, et al.
Journal of the International AIDS Society|June 12, 2021
Phase 1 pharmacokinetics and safety study of extended duration dapivirine vaginal rings in the United StatesAlbert Y Liu, Clara Dominguez Islas, Holly Gundacker, et al.
Plos One|January 14, 2025
Acceptability of a dapivirine levonorgestrel vaginal ring in two Phase 1 trials (MTN-030/IPM 041 and MTN-044/IPM 053/CCN019): Implications for multipurpose prevention technology developmentBarbara A Friedland, Holly Gundacker, Sharon L Achilles, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Pharmaceutical Research|August 1, 2014
Formulation and characterization of polymeric films containing combinations of antiretrovirals (ARVs) for HIV preventionAyman Akil, Hrushikesh Agashe, Charlene S Dezzutti, et al.
International Journal of Pharmaceutics|April 19, 2019
Development and pharmacokinetics of a combination vaginal ring for sustained release of dapivirine and the protein microbicide 5P12-RANTESJohn W McBride, R Karl Malcolm, Nicola Dias, et al.
Frontiers in Reproductive Health|July 24, 2023
Participant experiences with a multipurpose vaginal ring for HIV and pregnancy prevention during a phase 1 clinical trial: learning from users to improve acceptabilityMary Kate Shapley-Quinn, Mei Song, Beatrice A Chen, et al.
International Journal of Pharmaceutics|July 31, 2016
Matrix and reservoir-type multipurpose vaginal rings for controlled release of dapivirine and levonorgestrelPeter Boyd, Susan M Fetherston, Clare F McCoy, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 14, 2015
A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal FilmKatherine E Bunge, Charlene S Dezzutti, Lisa C Rohan, et al.
International Journal of Pharmaceutics: X|January 3, 2022
Silicone elastomer formulations for improved performance of a multipurpose vaginal ring releasing dapivirine and levonorgestrelYahya H Dallal Bashi, Diarmaid J Murphy, Clare F McCoy, et al.
Plos One|June 5, 2024
Phase 1 randomized trials to assess safety, pharmacokinetics, and vaginal bleeding associated with use of extended duration dapivirine and levonorgestrel vaginal ringsSharon L Achilles, Clifton W Kelly, Craig J Hoesley, et al.
The Lancet. HIV|February 4, 2021
Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension studyAnnalene Nel, Neliëtte van Niekerk, Ben Van Baelen, et al.
Journal of the International AIDS Society|June 12, 2021
Phase 1 pharmacokinetics and safety study of extended duration dapivirine vaginal rings in the United StatesAlbert Y Liu, Clara Dominguez Islas, Holly Gundacker, et al.
Plos One|January 14, 2025
Acceptability of a dapivirine levonorgestrel vaginal ring in two Phase 1 trials (MTN-030/IPM 041 and MTN-044/IPM 053/CCN019): Implications for multipurpose prevention technology developmentBarbara A Friedland, Holly Gundacker, Sharon L Achilles, et al.
Pageof 3